Abstract:Activation of the Nod-like receptor 3 (NLRP3) inflammasome is important for activation of innate immune responses, but improper and excessive activation can cause inflammatory disease. We previously showed that glycolysis, a metabolic pathway that converts glucose into pyruvate, is essential for NLRP3 inflammasome activation in macrophages. Here, we investigated the role of metabolic pathways downstream glycolysis – lactic acid fermentation and pyruvate oxidation—in activation of the NLRP3 inflammasome. Using pharmacological or genetic approaches, we show that decreasing lactic acid fermentation by inhibiting lactate dehydrogenase reduced caspase-1 activation and IL-1β maturation in response to various NLRP3 inflammasome agonists such as nigericin, ATP, monosodium urate (MSU) crystals, or alum, indicating that lactic acid fermentation is required for NLRP3 inflammasome activation. Inhibition of lactate dehydrogenase with GSK2837808A reduced lactate production and activity of the NLRP3 inflammasome regulator, phosphorylated protein kinase R (PKR), but did not reduce the common trigger of NLRP3 inflammasome, potassium efflux, or reactive oxygen species (ROS) production. By contrast, decreasing the activity of pyruvate oxidation by depletion of either mitochondrial pyruvate carrier 2 (MPC2) or pyruvate dehydrogenase E1 subunit alpha 1 (PDHA1) enhanced NLRP3 inflammasome activation, suggesting that inhibition of mitochondrial pyruvate transport enhanced lactic acid fermentation. Moreover, treatment with GSK2837808A reduced MSU-mediated peritonitis in mice, a disease model used for studying the consequences of NLRP3 inflammasome activation. Our results suggest that lactic acid fermentation is important for NLRP3 inflammasome activation, while pyruvate oxidation is not. Thus, reprograming pyruvate metabolism in mitochondria and in the cytoplasm should be considered as a novel strategy for the treatment of NLRP3 inflammasome-associated diseases.

Cathepsin B Is Required for NLRP3 Inflammasome Activation in Macrophages, Through NLRP3 Interaction

Phosphodiesterase 4B is Required for NLRP3 Inflammasome Activation by Positive Feedback with Nrf2 in the Early Phase of LPS- Induced Acute Lung Injury

NLRP3 regulates a non-canonical platform for caspase-8 activation during epithelial cell apoptosis

Apoptosis-Associated Speck-like Protein Containing a CARD Forms Specks but Does Not Activate Caspase-1 in the Absence of NLRP3 during Macrophage Swelling

NLRP3 phosphorylation in its LRR domain critically regulates inflammasome assembly

Cellular Localization of NLRP3 Inflammasome.

Β-Catenin Promotes NLRP3 Inflammasome Activation Via Increasing the Association Between NLRP3 and ASC

NLRP3 Activation and Mitosis Are Mutually Exclusive Events Coordinated by NEK7, a New Inflammasome Component

Lysosomal cathepsins act in concert with Gasdermin-D during NAIP/NLRC4-dependent IL-1β secretion

The Leucine-Rich Repeat (LRR) Domain of NLRP3 is Required for NLRP3 Inflammasome Activation in Macrophages

Acetylation is required for NLRP3 self-aggregation and full activation of the inflammasome

Activation of NLRP3 Inflammasome by Crystalline Structures Via Cell Surface Contact

Acetylation is required for full activation of the NLRP3 inflammasome

NLRP3 cages revealed by full-length mouse NLRP3 structure control pathway activation

Initiation and perpetuation of NLRP3 inflammasome activation and assembly

Β-Arrestin1 is Critical for the Full Activation of NLRP3 and NLRC4 Inflammasomes

Nek7 is an Essential Mediator of NLRP3 Activation Downstream of Potassium Efflux

Methods to Activate the NLRP1 Inflammasome.

Structural Mechanisms of NLRP3 Inflammasome Assembly and Activation

How location and cellular signaling combine to activate the NLRP3 inflammasome

Lactic Acid Fermentation Is Required for NLRP3 Inflammasome Activation